Orion Oyj (OTCMKTS:ORINF) Sees Significant Drop in Short Interest

Orion Oyj (OTCMKTS:ORINF) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 328,400 shares, a decline of 27.3% from the January 15th total of 451,800 shares. Based on an average daily volume of 200 shares, the short-interest ratio is currently 1,642.0 days.

Orion Oyj Stock Performance

Shares of ORINF stock remained flat at $48.65 during midday trading on Friday. 11 shares of the company’s stock were exchanged, compared to its average volume of 1,080. Orion Oyj has a one year low of $48.65 and a one year high of $48.65. The business has a 50 day simple moving average of $48.65 and a 200 day simple moving average of $47.74.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.